Marksans Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Marksans Pharma announced that a current Good Manufacturing Practices (cGMP) inspection was conducted by the USFDA at the manufacturing facility of the Company's wholly owned subsidiary Time-Cap Laboratories, Inc. located at 7, Michael Avenue, Farmingdale, New York, USA (?the Subsidiary?) from 16 April 2025 to 24 April 2025.

On conclusion of the inspection, the Subsidiary has received One (1) inspectional observation in Form 483. There is no data integrity observation. The Subsidiary will work closely with the USFDA and is committed to address the observation comprehensively within the stipulated time.

Powered by Capital Market - Live News

The inspection took place from April 16 to April 24, 2025, at the subsidiary's manufacturing facility in Farmingdale, New York.

At the end of the inspection, the subsidiary received one observation, documented in the USFDA's Form 483. Notably, the inspection did not raise any concerns regarding data integrity.

Marksans Pharma confirmed that it will work closely with the USFDA to address the observation within the prescribed timeline.

Marksans Pharma is engaged in the research, manufacturing & marketing of generic pharmaceutical formulations in the global markets. The company's manufacturing facilities are approved by several leading regulatory agencies including USFDA, UKMHRA, and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, antidiabetic, pain management, gastroenterological, and anti-allergies. the company is marketing these products globally.

The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24.

Powered by Capital Market - Live News

Marksans Pharma announced that its manufacturing facility located at Plot A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa has been approved by Australian TGA for manufacture of pharmaceutical formulations in Solid Dosage Forms of Tablets and hard Capsules for Australian markets.

The products will be manufactured at the above facility in Goa India and marketed & distributed in Australian markets through the Company's subsidiary Nova Pharmaceuticals Australasia.

Powered by Capital Market - Live News

The pharmaceutical formulations include solid dosage forms of tablets and hard capsules.

The products will be manufactured at the aforementioned facility located at Verna Industrial Estate, Verna, Goa, and marketed & distributed in Australian markets through the company?s subsidiary Nova Pharmaceuticals Australasia.

Marksans Pharma is primarily engaged in the business of research, manufacture, marketing, and sale of pharmaceutical formulations.

The company reported a 25.6% increase in consolidated net profit to Rs 104.56 crore on a 16.3% rise in revenue from operations to Rs 681.85 crore in Q3 FY25 over Q3 FY24.

Powered by Capital Market - Live News